Column: Is the magic-COVID pill really worth $1.2 billion?
This undated image provided by Merck & Co. shows their new antiviral medication. The drug maker has said its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths. The U.S. government signed a $1.2 billion deal to acquire 1.7 million courses of the drug. (Merck & Co. via AP)